Trials / Completed
CompletedNCT00549562
Study of Paliperidone ER in Adolescents and Young Adults With Autism
A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Young Adults With Autism
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Indiana University School of Medicine · Academic / Other
- Sex
- All
- Age
- 12 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paliperidone ER | Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2007-10-26
- Last updated
- 2017-05-16
- Results posted
- 2017-05-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00549562. Inclusion in this directory is not an endorsement.